Evaluation of Pharmacogenetic Testing In a Mental Health Population and Economic Outcomes — PGx-TIME  

Major Depressive Disorder 1 Clinical Trial

Official title: Evaluation of Pharmacogenetic Testing In a Mental Health Population and Economic Outcomes

Status Completed

Clinical Trial Summary

This is a non-randomized, single-case design of pharmacogenetic implementation in a mental health patient population of subjects taking antipsychotics and/or antidepressants.

Clinical Trial Description

This is a non-randomized, single-case design of pharmacogenetic implementation in a mental health patient population of subjects taking antipsychotics and/or antidepressants. Retrospective and prospective data will be collected on all subjects before and after pharmacogenetic recommendations have been made. Retrospective data will be collected for the previous 12 months before pharmacogenetic recommendations are made and prospective data will be collected for 12 months after pharmacogenomic recommendations have been made. ;

Related Conditions & MeSH terms

• Depression
• Depressive Disorder
• Depressive Disorder, Major
• Major Depressive Disorder 1

• NCT number: NCT02474680
• Study type: Observational
• Source: Avera McKennan Hospital & University Health Center
• Status: Completed
• Phase: N/A
• Start date: November 1, 2015
• Completion date: January 1, 2017